Haemoglobin control with epoetin beta: results from the cardiovascular risk reduction by early anaemia treatment with epoetin beta (CREATE) and anaemia correction in diabetes (ACORD) studies

被引：0
|
作者：
Clyne, Naomi
Macdougall, Iain
Bilous, Rudy
Ritz, Eberhard
机构：
[1] Sodertalje Hosp, Sodertalje, Sweden
[2] Kings Coll Hosp, London, England
[3] Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Univ Heidelberg, Heidelberg, Germany
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：169 / 169
页数：1
相关论文
共 13 条
  • [1] Anaemia correction with epoetin beta in patients with diabetes and chronic kidney disease - primary results of the Anaemia CORrection in Diabetes (ACORD) study
    Ritz, E.
    Bilous, R. W.
    de Alvaro, F.
    Laville, M.
    O'Donoghue, D.
    [J]. DIABETOLOGIA, 2006, 49 : 647 - 648
  • [2] Anemia correction with epoetin beta in patients with diabetes and chronic kidney disease - Primary results of the anaemia correction in diabetes (ACORD) study
    Ritz, Eberhard
    Bilous, Rudy W.
    de Alvaro, Fernando
    Laville, Maurice
    O'Donoghue, Donal
    Acherhag, Armin
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 11 - 11
  • [3] Cardiac impact of anemia correction with epoetin beta in patients with diabetes and chronic kidney disease: results of the anaemia correction in diabetes (ACORD) study
    Ritz, E.
    Bilous, R. W.
    De Alvaro, F.
    Laville, M.
    O'donoghue, D. J.
    Scherhag, A.
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 : 521 - 521
  • [4] Haemoglobin stability with epoetin beta:: Results from an interim analysis of the gain effectiveness in anaemia treatment with Neorecormon® (gain) observational study
    Rath, Thomas
    Rutkowski, Boleslaw
    Fischlova, Drahomira
    Lamas, Jose M.
    Mactier, Robert
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 167 - 167
  • [5] Characteristics of chronic kidney disease (CKD) patients enrolled in the 'Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta' (CREATE) study.
    Drueke, TB
    Clyne, N
    Eckardt, KU
    Locatelli, F
    Macdougall, IC
    Tsakiris, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 520A - 520A
  • [6] Impaired quality of life in chronic kidney disease patients enrolled in the cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) study.
    Tsakiris, D
    Clyne, N
    Drueke, TB
    Eckardt, KU
    Macdougall, IC
    Locatelli, F
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 456A - 456A
  • [7] Geographical distribution of cardiovascular disease characteristics of chronic kidney disease patients enrolled in the cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) study.
    Locatelli, F
    Clyne, N
    Drueke, TB
    Eckardt, KU
    Macdougall, LC
    Tsakiris, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 671A - 671A
  • [8] Left ventricular function and geometry variables in patients not receiving RRT enrolled in the 'Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin beta' (CREATE) trial.
    Eckardt, KU
    Clyne, N
    Drueke, TB
    Locatelli, F
    Macdougall, IC
    Tsakiris, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 523A - 523A
  • [9] USE OF METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA IN TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS- A CASE CONTROL STUDY
    Lamb, Angela
    Bhojani, Sheetal
    Krischock, Leah
    Ramage, Ian
    [J]. PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1792 - 1793
  • [10] Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy:: results of the NeoPrevent study
    de Castro, Javier
    Ordonez, Amalio
    Isla, Dolores
    Sanchez, Alfredo
    Arrivi, Antonio
    Manzano, Jose Luis
    Baron, Manuel Gonzalez
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (01) : 35 - 42
12